These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 16965866

  • 1. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial.
    Yeoh EE, Holloway RH, Fraser RJ, Botten RJ, Di Matteo AC, Butters J, Weerasinghe S, Abeysinghe P.
    Int J Radiat Oncol Biol Phys; 2006 Nov 15; 66(4):1072-83. PubMed ID: 16965866
    [Abstract] [Full Text] [Related]

  • 2. Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial.
    Yeoh EE, Botten RJ, Butters J, Di Matteo AC, Holloway RH, Fowler J.
    Int J Radiat Oncol Biol Phys; 2011 Dec 01; 81(5):1271-8. PubMed ID: 20934277
    [Abstract] [Full Text] [Related]

  • 3. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial.
    Yeoh EE, Fraser RJ, McGowan RE, Botten RJ, Di Matteo AC, Roos DE, Penniment MG, Borg MF.
    Int J Radiat Oncol Biol Phys; 2003 Mar 15; 55(4):943-55. PubMed ID: 12605972
    [Abstract] [Full Text] [Related]

  • 4. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T, Katoh H, Noda SE, Ito K, Yamamoto T, Kashiwagi B, Nakano T.
    Int J Radiat Oncol Biol Phys; 2005 Oct 01; 63(2):472-8. PubMed ID: 16168839
    [Abstract] [Full Text] [Related]

  • 5. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results.
    Madsen BL, Hsi RA, Pham HT, Fowler JF, Esagui L, Corman J.
    Int J Radiat Oncol Biol Phys; 2007 Mar 15; 67(4):1099-105. PubMed ID: 17336216
    [Abstract] [Full Text] [Related]

  • 6. Clinical and dosimetric predictors of acute toxicity after a 4-week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial.
    Arcangeli S, Strigari L, Soete G, De Meerleer G, Gomellini S, Fonteyne V, Storme G, Arcangeli G.
    Int J Radiat Oncol Biol Phys; 2009 Jan 01; 73(1):39-45. PubMed ID: 18538488
    [Abstract] [Full Text] [Related]

  • 7. Hypofractionated radiotherapy for favorable risk prostate cancer.
    Rene N, Faria S, Cury F, David M, Duclos M, Shenouda G, Souhami L.
    Int J Radiat Oncol Biol Phys; 2010 Jul 01; 77(3):805-10. PubMed ID: 20510194
    [Abstract] [Full Text] [Related]

  • 8. Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer.
    Fonteyne V, De Gersem W, De Neve W, Jacobs F, Lumen N, Vandecasteele K, Villeirs G, De Meerleer G.
    Int J Radiat Oncol Biol Phys; 2009 Nov 15; 75(4):1013-20. PubMed ID: 19386427
    [Abstract] [Full Text] [Related]

  • 9. Hypofractionated boost with high-dose-rate brachytherapy and open magnetic resonance imaging-guided implants for locally aggressive prostate cancer: a sequential dose-escalation pilot study.
    Ares C, Popowski Y, Pampallona S, Nouet P, Dipasquale G, Bieri S, Ozsoy O, Rouzaud M, Khan H, Miralbell R.
    Int J Radiat Oncol Biol Phys; 2009 Nov 01; 75(3):656-63. PubMed ID: 19250768
    [Abstract] [Full Text] [Related]

  • 10. Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma.
    Martin JM, Rosewall T, Bayley A, Bristow R, Chung P, Crook J, Gospodarowicz M, McLean M, Ménard C, Milosevic M, Warde P, Catton C.
    Int J Radiat Oncol Biol Phys; 2007 Nov 15; 69(4):1084-9. PubMed ID: 17606331
    [Abstract] [Full Text] [Related]

  • 11. Hypofractionated accelerated radiotherapy using concomitant intensity-modulated radiotherapy boost technique for localized high-risk prostate cancer: acute toxicity results.
    Lim TS, Cheung PC, Loblaw DA, Morton G, Sixel KE, Pang G, Basran P, Zhang L, Tirona R, Szumacher E, Danjoux C, Choo R, Thomas G.
    Int J Radiat Oncol Biol Phys; 2008 Sep 01; 72(1):85-92. PubMed ID: 18355982
    [Abstract] [Full Text] [Related]

  • 12. Salvage hypofractionated radiotherapy for biochemically recurrent prostate cancer after radical prostatectomy.
    Wong GW, Palazzi-Churas KL, Jarrard DF, Paolone DR, Graf AK, Hedican SP, Wegenke JD, Ritter MA.
    Int J Radiat Oncol Biol Phys; 2008 Feb 01; 70(2):449-55. PubMed ID: 17869014
    [Abstract] [Full Text] [Related]

  • 13. Anorectal function after three- versus two-dimensional radiation therapy for carcinoma of the prostate.
    Yeoh EK, Holloway RH, Fraser RJ, Botten R, Di Matteo A, Moore JW, Schoeman MN, Bartholomeusz DL.
    Int J Radiat Oncol Biol Phys; 2009 Jan 01; 73(1):46-52. PubMed ID: 18571336
    [Abstract] [Full Text] [Related]

  • 14. Comparison of the outcome and morbidity for localized or locally advanced prostate cancer treated by high-dose-rate brachytherapy plus external beam radiotherapy (EBRT) versus EBRT alone.
    Fang FM, Wang YM, Wang CJ, Huang HY, Chiang PH.
    Jpn J Clin Oncol; 2008 Jul 01; 38(7):474-9. PubMed ID: 18621848
    [Abstract] [Full Text] [Related]

  • 15. Hypofractionated radiotherapy denoted as the "Christie scheme": an effective means of palliating patients with head and neck cancers not suitable for curative treatment.
    Al-mamgani A, Tans L, Van rooij PH, Noever I, Baatenburg de jong RJ, Levendag PC.
    Acta Oncol; 2009 Jul 01; 48(4):562-70. PubMed ID: 19373698
    [Abstract] [Full Text] [Related]

  • 16. Accelerated radical radiotherapy for non-small cell lung cancer using two common regimens: a single-centre retrospective study of outcome.
    Pemberton LS, Din OS, Fisher PM, Hatton MQ.
    Clin Oncol (R Coll Radiol); 2009 Apr 01; 21(3):161-7. PubMed ID: 19111452
    [Abstract] [Full Text] [Related]

  • 17. Combined hypofractionated radiation and hormone therapy for the treatment of intermediate-risk prostate cancer.
    Yassa M, Fortin B, Fortin MA, Lambert C, Van Nguyen T, Bahary JP.
    Int J Radiat Oncol Biol Phys; 2008 May 01; 71(1):58-63. PubMed ID: 18406883
    [Abstract] [Full Text] [Related]

  • 18. Short-course versus split-course radiotherapy in metastatic spinal cord compression: results of a phase III, randomized, multicenter trial.
    Maranzano E, Bellavita R, Rossi R, De Angelis V, Frattegiani A, Bagnoli R, Mignogna M, Beneventi S, Lupattelli M, Ponticelli P, Biti GP, Latini P.
    J Clin Oncol; 2005 May 20; 23(15):3358-65. PubMed ID: 15738534
    [Abstract] [Full Text] [Related]

  • 19. Reduction of irradiation volume and toxicities with 3-D radiotherapy planning over conventional radiotherapy for prostate cancer treated with long-term hormonal therapy.
    Yamazaki H, Nishiyama K, Tanaka E, Maeda O, Meguro N, Kinouchi T, Usami M, Kakimoto K, Ono Y, Nishimura T.
    Anticancer Res; 2008 May 20; 28(6B):3913-20. PubMed ID: 19192649
    [Abstract] [Full Text] [Related]

  • 20. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer.
    Lukka H, Hayter C, Julian JA, Warde P, Morris WJ, Gospodarowicz M, Levine M, Sathya J, Choo R, Prichard H, Brundage M, Kwan W.
    J Clin Oncol; 2005 Sep 01; 23(25):6132-8. PubMed ID: 16135479
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.